All News

Eric Dein Tweet
#ACR23 @RheumNow #GreatDebate Treatment for PMR by Spiera - Plan rapid GC taper. It is OK to flare, prepare pt! - Low threshold to introduce anti-IL-6 for GC intolerance or AEs No need for initial biologic treatment for PMR/GCA @philseo rebuttal upcoming... https://t.co/A0f3b0fMOr
TheDaoIndex Tweet
KDAO2011
Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in disease. there had been cases where pts still had active vasculitis while on IL-6i. He starts with steroids first then add IL6i #GreatDebate #ACR23 @rheumnow https://t.co/Oq5Q9HFtW3
Janet Pope Tweet
#ACR23 #Debate Dr Spiera says NO need to up front use #glucocorticoid #sparing drugs in PMR - maybe only if flaring. Esp in PMR vs #GCA where maybe bDMARD in GCA in some Pts (my opinion) but for sure if failing #ACRbest #ACR23 @RheumNow @ACRheum https://t.co/Rt7rGZv3fW
Nouf Al hemmadi Tweet
1-Can we prevent RA ? Vagotomy? 2-CV events in auto immune rheumatic disease pregnancies. 3-CVS vasculitis , challenges and role of Brain biopsy And others…….. https://t.co/BX8bDSX1M3 @RheumNow , daily recap #ACR23
KenWarringtonMD Tweet
MdWarrington
⭐️Real world data on use of #avacopan presented by @zach_wallace_md #vasculitis Important observations to inform the practice and management of #AAV https://t.co/gtZORcnt9t
Alessia Alunno Tweet
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP) @TerrierBen #ACR23 #ACRambassador https://t.co/D8UfZvXQCl
Dr. Antoni Chan Tweet
Reduced-dose GC regimen in severe GPA or MPS (creatinine >300 umol/L, RTX as induction) associated with increased risk of death, ESKD, progression before remission requiring treatment modification or relapse, Nagle S Abst#0725 #ACR23 #ACRBest @RheumNow https://t.co/ZVZYRnSy3n
Richard Conway Tweet
LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free survival 92% vs 50%. Abstr#0854 #ACR23 @RheumNow https://t.co/76hlYRxWhY https://t.co/RSsgxxQKVC
sheila Tweet
Clinical pearls in #CNS vasculitis: Dr. R.Hajj-Ali 🧠Clinical dx is difficult bec it presents w/ an array of clinical features 🧠CSF analysis essential in dx; can r/o infexns 🧠Nonvasc imaging highly sensitive 🧠biopsy is valuable esp when alt dx is considered #ACR23 @RheumNow https://t.co/QOAfSHn8ND
Eric Dein Tweet
Risk factor for 1st Thrombosis in OB APS Ab#0115 #ACR23 @RheumNow 186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9) Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis #ACRBest https://t.co/y4KaEAZzA7
Mike Putman Tweet
EBRheum
Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
Eric Dein Tweet
Abst#0725 #ACR23 @RheumNow PEXIVAS Real life data! GPA & MPA pts - Retrosp observ study ⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx ⚠️Caution w/ reduced GC, RTX, severe kidney dis #ACRBest https://t.co/7qI5c1ZiqO
Robert B Chao, MD Tweet
Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
Richard Conway Tweet
Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×